Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer

Disseminated triple negative breast cancer (TNBC) is an incurable disease with limited therapeutic options beyond chemotherapy. Therefore, identification of druggable vulnerabilities is an important aim. Protein kinases play a central role in cancer and particularly in TNBC. They are involved in many oncogenic functions including migration, proliferation, genetic stability or maintenance of stem-cell like properties. In this article we describe a novel multi-kinase inhibitor with antitumor activity in this cancer subtype. EC-70124 is a hybrid indolocarbazole analog obtained by combinatorial biosynthesis of Rebeccamycin and Staurosporine genes that showed antiproliferative effect and in vivo antitumoral activity. Biochemical experiments demonstrated the inhibition of the PI3K/mTOR and JAK/STAT pathways. EC-70124 mediated DNA damage leading to cell cycle arrest at the G2/M phase. Pathway analyses identified several deregulated functions including cell proliferation, migration, DNA damage, regulation of stem cell differentiation and reversion of the epithelial-mesenchymal transition (EMT) phenotype, among others. Combination studies showed a synergistic interaction of EC-70124 with docetaxel, and an enhanced activity in vivo. Furthermore, EC-70124 had a good pharmacokinetic profile. In conclusion these experiments demonstrate the antitumor activity of EC-70124 in TNBC paving the way for the future clinical development of this drug alone or in combination with chemotherapy.

[1]  A. Esparís-Ogando,et al.  Therapeutic potential of ERK5 targeting in triple negative breast cancer , 2014, Oncotarget.

[2]  J. Montero,et al.  Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer , 2014, Oncogene.

[3]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[4]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[6]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[7]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[8]  M. Rao,et al.  Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase , 2011, Cell.

[9]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[10]  David R. Croucher,et al.  Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. , 2010, Cancer research.

[11]  J. Montero,et al.  Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. , 2010, Journal of the National Cancer Institute.

[12]  Jingsong Yuan,et al.  Focus on histone variant H2AX: To be or not to be , 2010, FEBS letters.

[13]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[14]  Antonio Pineda-Lucena,et al.  Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles. , 2009, Chemical communications.

[15]  Charles M. Perou,et al.  Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.

[16]  Boyoung Lee,et al.  Photic regulation of the mTOR signaling pathway in the suprachiasmatic circadian clock , 2008, Molecular and Cellular Neuroscience.

[17]  J Wade Harper,et al.  The DNA damage response: ten years after. , 2007, Molecular cell.

[18]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[19]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[20]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[21]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[22]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[23]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[24]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[27]  M. Kastan,et al.  The many substrates and functions of ATM , 2000, Nature Reviews Molecular Cell Biology.

[28]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[29]  S. Elledge,et al.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[31]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[32]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .